Edition:
United States

Otsuka Holdings Co Ltd (4578.T)

4578.T on Tokyo Stock Exchange

4,529JPY
22 Sep 2017
Change (% chg)

¥71 (+1.59%)
Prev Close
¥4,458
Open
¥4,488
Day's High
¥4,544
Day's Low
¥4,446
Volume
1,936,100
Avg. Vol
1,198,669
52-wk High
¥5,895
52-wk Low
¥4,290

Latest Key Developments (Source: Significant Developments)

Otsuka Holdings unit raises stake in India-based JV to 80 pct
Thursday, 21 Sep 2017 04:54am EDT 

Sept 21 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's wholly owned unit Otsuka Pharmaceutical Factory, Inc raises stake in JV Otsuka Pharmaceutical India Private Limited to 80 percent .Previous news was disclosed on May 8.  Full Article

Otsuka Holdings unit acquires Canada-based firm
Thursday, 31 Aug 2017 10:45pm EDT 

Sept 1 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's wholly owned unit Otsuka Pharmaceutical Co., Ltd. acquires Canada-based firm, which is mainly engaged in development, manufacture and sales of plant-based foods .  Full Article

Otsuka Holdings unit says ABILIFY MAINTENA® for extended-release injectable suspension approved by U.S. FDA
Sunday, 30 Jul 2017 10:33pm EDT 

July 31 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:* Says unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced ABILIFY MAINTENA®(aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and drug administration for the maintenance monotherapy treatment of bipolar I disorder (BP-I) in adults.  Full Article

Otsuka Pharmaceutical says ABILIFY MAINTENA for extended-release injectable suspension approved by U.S. FDA
Friday, 28 Jul 2017 10:38am EDT 

July 28 (Reuters) - Otsuka Pharmaceutical Co::ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension approved by U.S. FDA for maintenance monotherapy treatment of bipolar I disorder.Co, H. Lundbeck A/S announced ABILIFY MAINTENA for extended-release injectable suspension approved by U.S. FDA.  Full Article

R&I affirms Otsuka Holdings's rating at "AA-" and changes outlook to stable from negative
Wednesday, 19 Jul 2017 03:17am EDT 

July 19 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-"-R&I.* Rating outlook changed to stable from negative -R&I.  Full Article

Otsuka announces results of phase 3 data on tolvaptan
Monday, 22 May 2017 08:00am EDT 

May 22 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Otsuka announces results of phase 3 data on tolvaptan.Says primary and key secondary endpoints were positive for tolvaptan versus placebo in an additional phase 3 clinical trial.Data are intended to address complete response letter issued by FDA for a new drug application for tolvaptan in ADPKD in 2013.Says there were no new safety issues identified for tolvaptan during trial.  Full Article

Otsuka, Teva sign licensing agreement for Japan on TEV-48125
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Otsuka Pharmaceutical Co:Otsuka and Teva sign licensing agreement for Japan on prophylactic migraine drug candidate fremanezumab (TEV-48125).Teva Pharmaceutical Industries Ltd - with the agreement consummated, Otsuka is to pay Teva a lump-sum payment of $50 million.Teva Pharmaceutical Industries Ltd - future clinical trials in Japan will be carried out and funded by Otsuka.Teva Pharmaceutical Industries Ltd- in addition, Otsuka holds exclusive sales rights and will pay royalties on revenues to Teva.Teva Pharmaceutical-through agreement, otsuka secures exclusive rights in japan to fremanezumab, which teva is globally developing in other countries.  Full Article

Otsuka Holdings unit to buy 20 pct voting power in India JV
Monday, 8 May 2017 05:16am EDT 

May 8(Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says its wholly owned unit Otsuka Pharmaceutical Factory, Inc will buy 20 percent voting power in joint venture Otsuka Pharmaceutical India Private Limited (previous name Claris Otsuka Private Limited).JV is mainly engaged in intravenous nutrition products.Says unit will hold 80 percent voting power in the JV.  Full Article

RIBOMIC in discussion to continue joint research with Otsuka Pharmaceutical on RBM001
Wednesday, 11 Jan 2017 01:25am EST 

RIBOMIC Inc <4591.T> : Says co is in discussion to continue joint research with Otsuka Pharmaceutical Co Ltd on RBM001 (midkine aptamers targeted) .The former cooperation agreement have expired since Dec. 2016.  Full Article

Otsuka Holdings unit sells entire stake in VV Food & Beverage Co Ltd
Friday, 5 Aug 2016 05:35am EDT 

Otsuka Holdings Co Ltd <4578.T>: Says its indirect unit(directly held by Otsuka Pharmaceutical Co., Ltd.) sold entire stake in VV Food & Beverage Co Ltd on Aug. 5 .Says previous release disclosed on May 17.  Full Article

BRIEF-Otsuka Holdings unit raises stake in India-based JV to 80 pct

* Says co's wholly owned unit Otsuka Pharmaceutical Factory, Inc raises stake in JV Otsuka Pharmaceutical India Private Limited to 80 percent